Lv3
230 积分 2023-07-07 加入
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
25天前
已完结
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
25天前
已完结
Characteristics and outcomes ofRETrearranged Korean non-small cell lung cancerpatients in real-world practice
1个月前
已关闭
Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
2个月前
已完结
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
2个月前
已完结
Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy
2个月前
已完结
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
2个月前
已完结
Theimpact of adjuvant EGFR-TKls and 14-gene molecular assayon stage l non-small cell lung cancer with sensitive EGFRmutations
2个月前
已完结
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
3个月前
已完结
Antitumor Activity and Safety of DostarlimablMonotherapy in PatientsWith Mismatch Repair Deficient Solid TumorsA Nonrandomized Controlled Trial
3个月前
已完结
皖公网安备34019202002308
